Therefore, this study utilized primary human blood monocyte-derived macrophages and neutrophils from PwCF to examine how administration of MEK1/2 inhibitor compounds modulate CF macrophage TLR4 or TLR2-dependent pro-inflammatory responses and CF macrophage and neutrophil phagocytic capacity. This evidence concerns the gene TLR4 and cystic fibrosis.